• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.

作者信息

Speth Robert C

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.

Department of Pharmacology and Physiology, College of Medicine, Georgetown University, Washington, District of Columbia, USA.

出版信息

Drug Dev Res. 2020 Sep;81(6):643-646. doi: 10.1002/ddr.21672. Epub 2020 Apr 17.

DOI:10.1002/ddr.21672
PMID:32304146
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7264739/
Abstract
摘要

相似文献

1
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.对近期有关血管紧张素转换酶2（ACE2）和肾素-血管紧张素系统阻滞剂与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染相关性的评论的回应
Drug Dev Res. 2020 Sep;81(6):643-646. doi: 10.1002/ddr.21672. Epub 2020 Apr 17.
2
Mechanisms by which angiotensin-receptor blockers increase ACE2 levels.血管紧张素受体阻滞剂增加ACE2水平的机制。
Nat Rev Cardiol. 2020 Jun;17(6):378. doi: 10.1038/s41569-020-0387-7.
3
Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research.新型冠状病毒肺炎与血管紧张素转换酶2（ACE2）：研究领域
Heart Lung. 2020 Jul-Aug;49(4):351. doi: 10.1016/j.hrtlng.2020.04.012. Epub 2020 Apr 20.
4
Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?肾素-血管紧张素-醛固酮系统抑制剂对2019冠状病毒病死亡率的影响：血管紧张素转换酶2的下一步是什么？
Clin Infect Dis. 2020 Nov 19;71(16):2129-2131. doi: 10.1093/cid/ciaa627.
5
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.血管紧张素转换酶（ACE）抑制剂与血管紧张素II受体阻滞剂对2019冠状病毒病死亡风险的比较影响
Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3.
6
Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.SARS-CoV-2 与肾素血管紧张素系统相互作用的临床意义：美国心脏病学会评论专题周报。
J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.
7
Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?血管紧张素转换酶2（ACE2）的下调会导致新型冠状病毒肺炎（COVID-19）中肾素-血管紧张素系统的过度刺激：我们应该阻断肾素-血管紧张素系统吗？
Hypertens Res. 2020 Aug;43(8):854-856. doi: 10.1038/s41440-020-0476-3. Epub 2020 May 22.
8
[ACE2 and coronavirus - a question of balance and dynamics?].[血管紧张素转换酶2与冠状病毒——平衡与动态变化的问题？]
Lakartidningen. 2020 Apr 17;117:F3S3.
9
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎关系的Meta分析
Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2.
10
[Renin Angiotensin Axis, Angiotensin Converting Enzyme 2 and Coronavirus].[肾素-血管紧张素轴、血管紧张素转换酶2与冠状病毒]
Rev Chil Pediatr. 2020 Jun;91(3):330-338. doi: 10.32641/rchped.vi91i3.2548.

引用本文的文献

1
Nanoparticle approaches for the renin-angiotensin system.用于肾素-血管紧张素系统的纳米颗粒方法。
Heliyon. 2023 Jun 2;9(6):e16951. doi: 10.1016/j.heliyon.2023.e16951. eCollection 2023 Jun.
2
Biologia Futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients?未来生物学：ADAM17 是否是糖尿病和高血糖患者易感染 COVID-19 的原因？
Biol Futur. 2021 Sep;72(3):291-297. doi: 10.1007/s42977-021-00092-2. Epub 2021 Jun 8.
3
Recent advances in developing small-molecule inhibitors against SARS-CoV-2.开发针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的小分子抑制剂的最新进展。
Acta Pharm Sin B. 2022 Apr;12(4):1591-1623. doi: 10.1016/j.apsb.2021.06.016. Epub 2021 Jul 2.
4
A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics.基于植物表达系统生产疫苗及植物生物技术应对新冠病毒大流行的综述
Plants (Basel). 2021 Jun 15;10(6):1213. doi: 10.3390/plants10061213.
5
COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.新型冠状病毒肺炎：感染期间多个系统失衡和心脏及抗凝治疗选择及剂量的重要性。
Mol Biol Rep. 2021 Mar;48(3):2917-2928. doi: 10.1007/s11033-021-06333-w. Epub 2021 Apr 10.
6
Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?在两次风暴之间，血管活性肽或缓激肽是 COVID-19 严重程度的基础？
Physiol Rep. 2021 Mar;9(5):e14796. doi: 10.14814/phy2.14796.
7
Metabolism of angiotensin peptides by angiotensin converting enzyme 2 (ACE2) and analysis of the effect of excess zinc on ACE2 enzymatic activity.血管紧张素肽的代谢由血管紧张素转换酶 2（ACE2）完成，并分析锌过量对 ACE2 酶活性的影响。
Peptides. 2021 Mar;137:170477. doi: 10.1016/j.peptides.2020.170477. Epub 2021 Jan 2.
8
An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease.治疗新冠病毒疾病的治疗药物最新综述
Clin Pharmacol. 2020 Dec 14;12:203-212. doi: 10.2147/CPAA.S284809. eCollection 2020.
9
Immunotherapy for SARS-CoV-2: potential opportunities.新型冠状病毒肺炎的免疫疗法：潜在机遇
Expert Opin Biol Ther. 2020 Oct;20(10):1111-1116. doi: 10.1080/14712598.2020.1807933. Epub 2020 Aug 12.

本文引用的文献

1
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
2
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
3
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
4
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.严重急性呼吸系统综合征冠状病毒 2 刺突糖蛋白的结构、功能和抗原性。
Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058. Epub 2020 Mar 9.
5
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.血管紧张素受体阻滞剂可作为治疗 SARS-CoV-2 的候选药物。
Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.
6
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.针对源自中国武汉的新型冠状病毒在疫情爆发情况下的治疗策略。
F1000Res. 2020 Jan 31;9:72. doi: 10.12688/f1000research.22211.2. eCollection 2020.
7
Angiotensin II and leukocyte trafficking: New insights for an old vascular mediator. Role of redox-signaling pathways.血管紧张素 II 与白细胞迁移：一种新的血管介质的新见解。氧化还原信号通路的作用。
Free Radic Biol Med. 2020 Sep;157:38-54. doi: 10.1016/j.freeradbiomed.2020.02.002. Epub 2020 Feb 11.
8
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.新型冠状病毒受体识别：基于 SARS 冠状病毒长达十年结构研究的分析。
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.00127-20.
9
ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway.ACE2 通过抑制 LPS-TLR4 通路对 LPS 诱导的小鼠急性肺损伤发挥保护作用。
Exp Mol Pathol. 2020 Apr;113:104350. doi: 10.1016/j.yexmp.2019.104350. Epub 2019 Dec 2.
10
Role of ADAM17 in kidney disease.ADAM17在肾脏疾病中的作用。
Am J Physiol Renal Physiol. 2019 Aug 1;317(2):F333-F342. doi: 10.1152/ajprenal.00625.2018. Epub 2019 May 29.